Referencia número: HY-100463

TPI-1

21 Cited Publications

Revisión del cliente

Based on 21 publication(s) in Google Scholar

TPI-1, also known as Tyrosine Phosphatase Inhibitor 1, is a SHP-1 inhibitor; inhibits recombinant SHP-1 with an IC₅₀ of 40 nM.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 98.0%
No. CAS: 79756-69-7
Fòrmula: C₁₂H₆Cl₂O₂
Peso molecular:253.08

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

TPI-1 Chemical Structure

No. CAS: 79756-69-7

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (21)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

TPI-1, also known as Tyrosine Phosphatase Inhibitor 1, is a SHP-1 inhibitor; inhibits recombinant SHP-1 with an IC₅₀ of 40 nM.

IC₅₀ & Target

IC50: 40 nM (recombinant SHP-1)^[1]

In Vitro

SHP-1 has been implicated as a potential cancer therapeutic target. TPI-1 is effective starting at 10 ng/mL in increasing SHP-1 phospho-substrates pLck-pY394. TPI-1 selectively increases SHP-1 phospho-substrates (pLck-pY394, pZap70 and pSlp76) in Jurkat T cells but has little effects on pERK1/2 or pLck-pY505. TPI-1 induces mouse splenic-IFNγ⁺ cells and induces IFNγ⁺ cells in human peripheral blood^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TPI-1 inhibits the growth of B16 melanoma tumors in mice at a tolerated oral dose in a T cell-dependent manner but has little effects on B16 cell growth in culture. TPI-1 thus also increases pLck-pY394 and IFNγ⁺ cells in mice. TPI-1 also inhibits B16 tumor growth and prolongs tumor mice survival as a tolerated s.c. agent^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 79756-69-7
Appearance Solid
Peso molecular 253.08
Fòrmula C₁₂H₆Cl₂O₂
Color White to yellow
SMILES

ClC1=CC(C2=CC(C=CC2=O)=O)=C(Cl)C=C1
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (21)

All RT-PCRIn Vivo Efficacy StudyWBELISA

Sort by:

Journal Impact Factor

Nat Immunol

Kupffer cell calibration of T cell responses via VSIG4-CD5 interaction promotes tumor evasion. [Abstract]

2026 Jun;27(6):1253-1267. PMID: 42056254
Immunity

Macrophage metabolic exhaustion and PANoptotic cell death drive chronic tissue inflammation in rheumatoid arthritis. [Abstract]

2026 Mar 6:S1074-7613(26)00040-3. PMID: 41794034
Nat Metab

Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation. [Abstract]

2021 Apr;3(4):513-522. PMID: 33846641
Cancer Res

Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis. [Abstract]

2022 May 16;82(10):1991-2002. PMID: 35364609
J Allergy Clin Immunol

LAIR-1 acts as an immune checkpoint on activated ILC2s and regulates the induction of airway hyperreactivity. [Abstract]

2022 Jan;149(1):223-236.e6. PMID: 34144112

TPI-1 purchased from MedChemExpress. Usage Cited in: J Allergy Clin Immunol. 2022 Jan;149(1):223-236.e6. [Abstract]

TPI-1 (15 μM). Representative histograms of SHP-1 expression in WT and LAIR-1 KO ILC2s and their corresponding MFI quantification.
J Immunother Cancer

Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition. [Abstract]

2025 Apr 17;13(4):e010879. PMID: 40246583

TPI-1 purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2025 Apr 17;13(4):e010879. [Abstract]

Mice bearing YUMM 1.1 tumors were treated intraperitoneally (i.p.) with TPI-1 (3 mg/kg) in combination with ICI (anti-PD-1 and anti-CTLA), or singly with either TPI-1 or ICI, every 3 days beginning at the time of tumor visibility (day 7–10).
Cancer Lett

Neutrophil extracellular traps enhance platinum resistance in ovarian cancer via SHP-1 activation. [Abstract]

2026 Apr 10:643:218288. PMID: 41620200
J Neuroinflammation

DJ-1 exerts anti-inflammatory effects and regulates NLRX1-TRAF6 via SHP-1 in stroke. [Abstract]

2020 Mar 9;17(1):81. PMID: 32151250

TPI-1 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2020 Mar 9;17(1):81. [Abstract]

After overexpressing DJ-1 and inhibiting SHP-1 with virus and TPI-1 (10 ng/ml), respectively, the expression of NLRX1, TRAF6 and SHP-1 in rat brain tissue was detected by Western blotting.
Phytother Res

Quercetin Alleviates Chronic Urticaria by Negatively Regulating IgE-Mediated Mast Cell Activation Through CD300f. [Abstract]

2025 Jul;39(7):3033-3045. PMID: 40309955
Front Immunol

Antibody-Mediated LILRB2-Receptor Antagonism Induces Human Myeloid-Derived Suppressor Cells to Kill Mycobacterium tuberculosis. [Abstract]

2022 Jun 10:13:865503. PMID: 35757769

TPI-1 purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jun 10:13:865503. [Abstract]

TPI-1 (1 μg/mL). Supernatant was collected 18 hours post-infection, and cytokines were detected using a sandwich ELISA method.
Front Immunol

SIRPα Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients. [Abstract]

2021 Jan 21:11:610523. PMID: 33552071
PLoS Pathog

The protein segregase VCP/p97 promotes host antifungal defense via regulation of SYK activation. [Abstract]

2024 Oct 29;20(10):e1012674. PMID: 39471181

TPI-1 purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2024 Oct 29;20(10):e1012674. [Abstract]

Wild-type and VCP-deficient BMDM cells were pretreated with DMSO or the SHP1 inhibitor TPI-1 (10 μM) for 1 hour, then stimulated with ZymD at specified time points, followed by Western blot analysis.
Int Immunopharmacol

Clarithromycin-treated chronic spontaneous urticaria with the negative regulation of FcεRΙ and MRGPRX2 activation via CD300f. [Abstract]

2022 Sep:110:109063. PMID: 35853276
Am J Physiol Cell Physiol

Retraction for Su et al., SHP-1 aggravates obesity-related glomerulopathy and palmitic acid-induced podocyte injury via regulating the PI3K/Nrf2/SIRT1 axis. [Abstract]

2022 Aug 1;323(2):C650. PMID: 35264015
J Neurochem

DJ-1 regulates astrocyte activation through miR-155/SHP-1 signaling in cerebral ischemia/reperfusion injury. [Abstract]

2025 Jan;169(1):e16230. PMID: 39323054
Cell Signal

Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling. [Abstract]

2026 Feb:138:112204. PMID: 41177417
Cell Signal

Combination of Cbl-b inhibitor NX-1607 and CDK4/6 inhibitor abemaciclib enhances anti-tumor immunity through PLCγ1/ERK-mediated T cell activation. [Abstract]

2025 Nov:135:112051. PMID: 40774352
J Immunol Res

Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways. [Abstract]

2020 Jun 19;2020:4598476. PMID: 33123602
J Stroke Cerebrovasc Dis

Downregulation of NF-κB by Shp-1 Alleviates Cerebral Venous Sinus Thrombosis-Induced Brain Edema Via Suppression of AQP4. [Abstract]

2022 Aug;31(8):106570. PMID: 35636226
Charles University

2026.
bioRxiv

Inclusion of the ζ-chain drives phosphotyrosine signalling in CD19-CAR T cells. [Abstract]

2025 Jul 7:2025.07.04.663030. PMID: 40672291

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (197.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9513 mL

19.7566 mL

39.5132 mL

5 mM

0.7903 mL

3.9513 mL

7.9026 mL

10 mM

0.3951 mL

1.9757 mL

3.9513 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Animal Administration^[1]

Mice: For in vivo induction of pLck-pY394 and IFNγ+ cells in mice, C57BL/6J mice are treated with PBS or TPI-1 (1 or 3 mg/kg, s.c.) for 4 days. Spleens are harvested one hour post-treatment on day 4 and processed into splenocytes, which are used for assessing pLck-pY394 levels by SDS-PAGE/Western blotting and for quantification of IFNγ+ cells by ELISPOT assays. Mice are also treated with TPI-1 (10 mg/kg, daily, s.c.) to evaluate the toxicity of the compounds in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Kundu S, et al. Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. J Immunol. 2010 Jun 1;184(11):6529-36. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9513 mL	19.7566 mL	39.5132 mL	98.7830 mL
	5 mM	0.7903 mL	3.9513 mL	7.9026 mL	19.7566 mL
	10 mM	0.3951 mL	1.9757 mL	3.9513 mL	9.8783 mL
	15 mM	0.2634 mL	1.3171 mL	2.6342 mL	6.5855 mL
	20 mM	0.1976 mL	0.9878 mL	1.9757 mL	4.9391 mL
	25 mM	0.1581 mL	0.7903 mL	1.5805 mL	3.9513 mL
	30 mM	0.1317 mL	0.6586 mL	1.3171 mL	3.2928 mL
	40 mM	0.0988 mL	0.4939 mL	0.9878 mL	2.4696 mL
	50 mM	0.0790 mL	0.3951 mL	0.7903 mL	1.9757 mL
	60 mM	0.0659 mL	0.3293 mL	0.6586 mL	1.6464 mL
	80 mM	0.0494 mL	0.2470 mL	0.4939 mL	1.2348 mL
	100 mM	0.0395 mL	0.1976 mL	0.3951 mL	0.9878 mL

Keywords

TPI-1

21 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

TPI-1

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Phosphatase Inhibitor Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) TPI-1

Actividad biológica

Chemical Information

Publications (21)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

TPI-1

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Phosphatase Inhibitor Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) TPI-1

Actividad biológica

Chemical Information

Publications (21)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

TPI-1 Related Classifications

HY-100463 Related Classifications